drugset / Trial / NCT01666951

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

NCT01666951

Phase 2 Completed 36 enrolled Veloxis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.

Timeline

Start
2012-11
Primary completion
2013-03
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule

Indications